Pulmatrix Inc PULM

Morningstar Rating
$1.72 −0.08 (4.44%)
View Full Chart

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

PULM is trading at a LOCK|&l$yR? premium.
Price
$1.75
Fair Value
LOCK|$>%r>&B
Uncertainty
LOCK|r? mW&#q
1-Star Price
LOCK|$my&TxQ
5-Star Price
LOCK|%B#?!<
Economic Moat
LOCK|$^
Capital Allocation

News

Trading Information

Previous Close Price
$1.80
Day Range
$1.621.79
52-Week Range
$1.166.83
Bid/Ask
$1.20 / $1.77
Shares Outstanding
3.65M
Market Cap
$6.28M
Volume/Avg
46,121 / 54,585

Key Statistics

Price/Earnings (Normalized)
Price/Sales
Dividend Yield (Trailing)
0.00%
Dividend Yield (Forward)
0.00%
Total Yield

Company Profile

Pulmatrix Inc is a biopharmaceutical company focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory diseases with important unmet medical needs using its patented dry powder delivery technology, iSPERSE. Its pipeline of clinical assets includes PUR3100 for the treatment of acute migraine, PUR1800 for the treatment of acute exacerbations of chronic obstructive pulmonary disease (AECOPD), and PUR1900 for the treatment of ABPA in patients with asthma and in patients with cystic fibrosis (CF).
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Small Value
Total Number of Employees
2

Valuation

Metric
PULM
Price/Earnings (Normalized)
Price/Book Value
2.39
Price/Sales
Price/Cash Flow
Price/Earnings
PULM

Financial Strength

Metric
PULM
Quick Ratio
3.67
Current Ratio
4.96
Interest Coverage
Quick Ratio
PULM

Profitability

Metric
PULM
Return on Assets (Normalized)
−81.00%
Return on Equity (Normalized)
−94.15%
Return on Invested Capital (Normalized)
−92.63%
Return on Assets
PULM

Biotechnology Industry Comparables

1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Vertex Pharmaceuticals Inc
VRTX
LOCK|$fbF%vnLOCK|%CDZD$123B
Regeneron Pharmaceuticals Inc
REGN
LOCK|r$Hzw<LOCK|nQmm%$70B
argenx SE ADR
ARGX
LOCK|$^G^Y#LOCK|&Y$$54B
Alnylam Pharmaceuticals Inc
ALNY
LOCK|!h>hqGTLOCK|?!Hf$40B
BeOne Medicines Ltd ADR
ONC
LOCK|R>D#XxLOCK|Hm$36B
Moderna Inc
MRNA
LOCK|BxXby$KLOCK|?^%$27B
Royalty Pharma PLC Class A
RPRX
LOCK|@MC!#vpLOCK|Rlh>$25B
Incyte Corp
INCY
LOCK|bdNp<GvLOCK|<Vk$23B
BioNTech SE ADR
BNTX
LOCK|!bmFwH&LOCK|x?v$23B
BridgeBio Pharma Inc
BBIO
LOCK|#?h!w$LOCK|hq&$17B

Sponsor Center